Recent News

• 09.16.2025 - Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
• 09.04.2025 - Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
• 08.13.2025 - Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
• 08.11.2025 - Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Recent Filings

• 09.04.2025 - EX-99.1 EX-99.1
• 09.04.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.11.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.11.2025 - 8-K Current report
• 08.08.2025 - 424B4 Prospectus [Rule 424(b)(4)]
• 08.08.2025 - 4 Statement of changes in beneficial ownership of securities